PFIZ34 trade ideas
PFE to take off soonNYSE:PFE Pfizer made a classic reversal and is now in retraction before next move up.
Is a long-mid time trade, anyway you will have around 6% dividends on your way as reward for waiting.
Q3 Trade PfizerQ3 results for Pfizer were solid, with adjusted earnings and revenue surpassing expectations. The current drop in share price seems excessive and may be driven by liquidity concerns rather than underlying performance issues. The significant decline in expected sales for COVID products is concerning, but overall, the fundamentals appear stable. This drop could present a buying opportunity if it’s mainly a liquidity grab
Pfizer BUY november 2024Long-term investment.
Macro Overview: Quality rules, the economy is trying to recover, but there's still too much uncertainty.
PFE Narrative:
Strong reports, yet the market reaction is muted. There's a deliberate offer to create negative sentiment, to prevent investors from believing in positive outcomes.
Thoughts:
Buy now. Current price $28.09
! NOT A RECOMMENDATION !
PFE chart update, Medicine is expensive So essentially, I tried to follow the trends.
When doing so, it does form an interesting pattern.
It almost looks like a long position chance.
It depends on where support lands with price action, and where the trend breakout occurs, as there is a nice gap setup on the charts that puts PFE on a climb and allows it to form a bullish long term trend.
Should trend break down past last support and confirm that underside exit, it would probably signal a bearish move is more likely.
However, It's a neat setup to watch.
good luck
Link to other PFE chart will be attached.
PFE painting a bottom? eyes on $ 28.60 immediate hurdlePFE is near Covid lows while others are flying.
No idea whats wrong or pharma/drug standing.
Chart says possible bottom or one more drop yet.
$ 28.56 - 28.63 is the immediate hurdle.
$ 28.18 - 28.26 is the current support.
$ 27.57 - 27.66 is best guess of bottom.
==========================================
.
Pfizer Stock Rises on Report Starboard Takes $1Bln StakePfizer Inc. (NYSE: NYSE:PFE ), once a market darling during the COVID-19 pandemic thanks to its breakthrough vaccine, has seen its stock struggle over the past two years. The shares are trading roughly 30% lower than in 2019 and have faced immense pressure due to declining demand for its COVID-related products and a costly acquisition strategy. However, a new catalyst has emerged that may signal a turning point for the pharmaceutical giant—activist investor Starboard Value has reportedly taken a $1 billion stake in Pfizer (NYSE: NYSE:PFE ), setting the stage for a potential turnaround. Let's dive into the technical and fundamental aspects driving this story.
A Billion-Dollar Vote of Confidence
Starboard Value's stake in Pfizer (NYSE: NYSE:PFE ), valued at roughly $1 billion, is a clear signal that the activist hedge fund believes there is untapped value in the company. Starboard has a track record of targeting underperforming companies and pushing for strategic changes to unlock shareholder value. This time, Starboard appears to be focusing on Pfizer’s management, specifically CEO Albert Bourla, who has been criticized for his acquisition-heavy strategy since taking the helm in 2019.
Under Bourla, Pfizer (NYSE: NYSE:PFE ) has spent close to $70 billion on acquisitions, including the $43 billion deal for Seagen in 2022, focused on cancer drugs. While Pfizer (NYSE: NYSE:PFE ) hoped these moves would diversify its revenue streams beyond COVID-19, many analysts and investors have questioned the returns on these investments, particularly after Pfizer (NYSE: NYSE:PFE ) recently had to recall a sickle cell drug it acquired in the $5 billion Global Blood Therapeutics acquisition. The drug Oxbryta, which brought in only $300 million last year, had to be pulled due to safety concerns, further denting investor confidence.
Starboard’s approach reportedly includes reaching out to Ian Read, Pfizer’s former CEO, and Frank D’Amelio, its former CFO, both of whom had a more disciplined focus on cost management and investment in novel drugs during their tenure. Under Read, Pfizer shares more than doubled, while Bourla’s leadership has coincided with a significant erosion in shareholder value.
To address these challenges, Pfizer (NYSE: NYSE:PFE ) has already initiated a $4 billion cost-cutting program and is planning further reductions. However, more than $100 billion in shareholder value has evaporated since the peak of the pandemic, putting immense pressure on management to act swiftly.
Technical Outlook
From a technical perspective, Pfizer’s stock has been in a downward trend since its pandemic highs in 2021. However, the recent news of Starboard’s involvement has injected new life into the stock, which is up around 3% in premarket trading. This spike is also above key moving averages, suggesting a potential shift in momentum.
The (Relative Strength Index) RSI currently sits at 42.59, which is just below neutral territory. While not yet in the overbought range, this indicates the stock still has room to run, particularly as investor sentiment improves following the Starboard news. The RSI suggests that the stock may be exiting its oversold condition, aligning with a bullish outlook.
Pfizer has been trading in a falling trend pattern, characterized by lower highs and lower lows. However, the recent surge in premarket trading suggests a potential break from this pattern. If the stock can maintain its momentum and break through key resistance levels, we could see a reversal in its overall trend.
NYSE:PFE has moved above several key moving averages, which often serve as support and resistance levels. Breaking above these averages can be a bullish signal for traders, especially in combination with improving fundamentals driven by Starboard’s involvement.
Market Performance vs. Peers
Pfizer's shares have been relatively flat in 2024, underperforming the broader market, which has seen a 21% rise in the S&P 500. This poor performance is in part due to fading COVID-19-related revenues and costly acquisitions that have yet to yield significant returns. The company’s stock is currently about 50% below its pandemic peak.
However, it’s worth noting that while Pfizer (NYSE: NYSE:PFE ) has underperformed, it still maintains a massive market capitalization, and its core pharmaceutical business remains strong. The company’s portfolio includes blockbuster drugs and a robust pipeline of potential therapies, particularly in oncology. Should Starboard’s involvement lead to a more disciplined approach to M&A and cost management, Pfizer could be well-positioned for a resurgence.
Outlook: Can Starboard Revive Pfizer?
While it’s too early to say definitively what Starboard's exact plans are for Pfizer, the involvement of an activist investor of this magnitude is often a positive signal for shareholders. Starboard has historically been successful in unlocking value in companies, and if Pfizer’s management is willing to make the necessary changes, we could see a significant turnaround in its stock price.
Pfizer Long potential with nice RRHere are the reasons for long:
1. We are in bullish zone (50%).
2. Price made a flip.
3. Small bullish divergence on RSI
4. Bullish volume confirmation
5. Bullish candlestick pattern
RR from 1:4 to 1:5 depending on loss aversion
VSA score on day 30.09: 675
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name
during the pandemic, now faces a pivotal moment.
Activist investor Starboard Value has taken a $1 billion
stake, signaling potential changes on the horizon. But
what does this mean for Pfizer's future?
The company that swiftly developed a COVID-19 vaccine
now grapples with declining sales and a tumbling
stock price. Starboard's involvement brings both challenge and
opportunity. Will this be the catalyst for Pfizer's
renaissance or a sign of deeper troubles ahead?
Former Pfizer executives have been approached to assist
in the turnaround effort. Their potential involvement adds
an intriguing layer to this unfolding story. Could
their experience and insight be the key to
unlocking Pfizer's next chapter of success and innovation?
As the pharmaceutical landscape evolves post-pandemic, Pfizer's
response to this pressure could set industry trends.
Cost-cutting, strategic refocusing and potential leadership changes loom
large. How will these moves impact drug development,
patient care, and the broader healthcare ecosystem?
For investors, patients, and industry watchers, Pfizer's
next moves are crucial. Will the company
emerge stronger, leaner, and more innovative? Or will
it struggle to find its footing in a
rapidly changing market? The answers to these questions
could reshape the future of global healthcare.
EZ EZApologies for the sloppy chart as I need to share this without putting to much effort into making it look pretty.
Look at the last earnings report EPS and tell me that big institutions aren't looking at this to buy...
Its consolidated enough so far and this is bound to hit $34-$36 EZ PZ.
Head and shoulderAscending channel breakout followed by a complete head and shoulder
I expect a bearish move during next week
PFIZER, targeting $50! Upside Prospect ON!PFE weekly data is conveying significant accumulation at the current price range.
Net positive volume has been increasing on a daily basis for the past few days -- in anticipation of the company's incoming price growth, long term.
The stock is currently sitting at 78.6 FIB level -- a discounted level where buyers converge.
Expect some significant bounce from the current range with initial target to $50.
Weekly higher lows on histogram has been registered. Trend shift is about to commence.
First Bubble up volume appearance in almost 2 months.
Spotted at 38.0
TAYOR
Safeguard capital always.
Pfizer got back on the rail Locally the trend has changed to the bullish side and price has returned inside of the channel. The bottom boundary of the channel has been tested successfully, and now I'm waiting the price to test the upper boundary of this channel. Currently, the price is moving inside the small rising channel and the bottom boundary of that channel works as a support.
Trade cancellation will occur in case if price would fix below 27.8 with 2 candles on daily basis.
Target is mentioned on chart.
DYOR
WDAY NASDAQ:WDAY
Short-Term (Hourly/Daily View):
Trend: Consolidation/Bearish with potential support retest.
Trade Direction: Consider shorting on any failed rally toward the $260 region or if the price breaks below the $240 area. Alternatively, look for long positions near the $240-$245 region with a tight stop loss if the price finds support at the 200-period EMA.
Long-Term (Weekly View):
Trend: Bullish on the weekly chart, with the trend intact but a potential pullback.
Trade Direction: Consider going long near the $240 level on any retracement towards the 20-period EMA. A break above $270 would indicate a continuation of the uptrend for a longer-term trade.
PFE (Y24.P3.E1). Sideways as part of wave 3 to 4Hi traders,
My thoughts on Pfizer to bottom out.
My level of interest is based on my common values for Elliott wave count based on a few assumptions. If it plans out, we will look for a long.
For now, expect a breakdown with this rising channel as the LH and LL overlap, bearish in nature.
All the best,
S.SAri
PFE . PfizerUS companies engaged in health technology sector
These US companies operate in the same sector, health technology. They're equipped with price, change, and other stats to help you get the most details. The list contains stocks for any strategy: giants with large caps like Eli Lilly and Company, top gainers like Portage Biotech Inc., and more. Filter the list and check companies' performance in a convenient way.
www.tradingview.com
$PFE | Allocation/Buy Trade | Market Exec |Technical Confluences:
- Price is in Oversold Conditions in D1 timeframe
- Price action bouncing off 150% Fibo Extension
- Price is trying to go back above the Interest Zone to give some bullish momentum to the stock
Fundamental Confluences:
-Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry
- They had a good response on a testing of their recent respiratory drug
- Value?
----
Health sector in your Portfolio will never be wrong with the global aging population.
I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE.
Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown.
-----
Is Pfizer Trying to Turn?Pfizer has struggled for years, but some traders may see signs of a turn.
The first pattern on today’s chart is the pair of positive moves after stronger-than-expected earnings reports. Those may reflect improving fundamentals for the drugmaker.
Second, the 50-day simple moving average (SMA) had a “golden cross” above the 200-day SMA last month. Has the longer-term trend improved?
Next, PFE made a lower low on Tuesday versus Monday and a higher high. That “outside day” may be viewed as a potentially bullish reversal pattern.
Finally, stochastics turned up after hitting an oversold condition.
TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. See our Overview for more.
Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors.
Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges.
TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
Classic Wyckoff accumulation. Markup phase coming ! This video is an analysis on the Wyckoff accumulation setup. All aspects of the method are being checked off so it's just a matter of time before we get a breakout due to a "catalyst in the news". Obviously, good news for the vaccine sector will probably be bad news for the overall market.
PFE Long PositionHi traders,
The price has been in the uptrend since April 2024 and we expect a pullback to retest the upsloping support level.which would be our entry.
Our target for this position would be at the upsloping resistance.
Good luck
$PFE Pfizer. Rounded bottom breakoutNice rounded bottom breakout and retest @ $29,30 level. If this level holds the target would be $33,50. 15% Upside on a good dividend payer.
PFE is it completed the Accumulation and Going to Fly ?! It is the first time to break out the wide range since DEC 2023
Now We are in Phase E ( Trading outside the Range) - Wyckoff Method
Supply showing Effort with no result
Demand has Increased
Also there is upcoming earning
so, Is the accumulation phase has completed and we are going to 🚀 ?!
TP 01 : 34.71
TP 02: 37.17
SL: 29.30
I am Just sharing insights and market trends for learning and growing every day and it is not financial advice.
